Originally published in Epilepsia
Some people with epilepsy continue to experience seizures even after trying multiple anti-seizure medications. This is known as drug-resistant epilepsy. For some of these individuals, surgery may be an option. However, identifying exactly where seizures begin in the brain can be challenging, particularly when MRI scans do not show an obvious abnormality.
One technique used to identify seizure-generating areas is called stereoelectroencephalography (SEEG). SEEG involves placing thin electrodes into specific areas of the brain to record electrical activity and identify where seizures begin. These same electrodes can sometimes be used to deliver a treatment called radiofrequency thermocoagulation (RF-TC). This technique uses controlled heat to create a small area of tissue damage around selected electrode contacts, with the goal of disrupting the brain tissue involved in generating seizures.
A recent study examined more than 20 years of experience using SEEG-guided RF-TC to determine how effective and safe this treatment is for people with drug-resistant focal epilepsy. Researchers reviewed the medical records of 244 patients with drug-resistant focal epilepsy who received SEEG-guided RF-TC at their center between 2001 and 2024. Patients were followed to assess their seizure outcomes at different intervals.
The researchers found many patients experienced an early improvement in seizures. Furthermore, although RF-TC can provide meaningful seizure reduction, maintaining complete seizure freedom over the long term is more difficult. Patients who responded well during the first 2 months after treatment were more likely to have favorable outcomes following subsequent epilepsy surgery. However, an early lack of improvement did not necessarily mean that subsequent surgery would be unsuccessful. Repeating the treatment may improve seizure control.
Some patients underwent additional RF-TC treatments during the first year. Patients who received repeat treatment were much more likely to experience clinical improvement. However, the study does not establish that repeating treatment will benefit every patient.
Certain brain characteristics may influence treatment success. The researchers found that patients with different underlying brain abnormalities had different treatment outcomes. Focal cortical dysplasia, an abnormal development of the brain’s outer layer, was the most frequently identified structural abnormality. Approximately 41% of patients had no obvious abnormality on their MRI scans. Treating a greater number of electrode contacts was associated with a lower likelihood of seizure freedom at 1 year.
These findings suggest that the underlying cause and location of epilepsy, as well as the extent of tissue treated, may influence treatment effectiveness. Although complications are possible, findings suggest that SEEG-guided RF-TC has a relatively low rate of serious lasting neurological complications.
This study demonstrates that SEEG-guided radiofrequency thermocoagulation can be a relatively safe treatment option for selected patients with drug-resistant focal epilepsy. Many patients experienced meaningful seizure reduction shortly after treatment, although complete and sustained seizure freedom was less common over the long term.
Overall, RF-TC may be particularly valuable as an initial therapeutic approach for patients undergoing SEEG evaluation, potentially providing seizure relief while helping clinicians make decisions about additional surgical treatment.